Literature DB >> 33168513

[Small interfering RNA-mediated programmed cell death-ligand 1 silencing in human glioma cells enhances human CD8+ T lymphocyte cytotoxicity in vitro].

Zhen Wang1,2,3, Wen Huang1, Bohong Cen1, Yuanyi Wei1, Lumin Liao1, Guoxian Li1, Aimin Ji1,2,4.   

Abstract

OBJECTIVE: To investigate the effect of small interfering RNA (siRNA)-mediated silencing of programmed cell deathligand 1 (PD-L1) in human glioma cells on the cytotoxicity of human CD8+T lymphocytes against the modified tumor cells.
METHODS: A siRNA sequence targeting PD-L1 gene was designed and transfected into human glioma U87 MG cells via lipofectamine 2000, and the gene silencing effect was validated using RT-qPCR, Western blotting, and flow cytometry. The transfected cells were co-cultured with human CD8+T lymphocytes, and the apoptosis of the tumor cells was analyzed with flow cytometry.
RESULTS: The siRNA sequence showed strong PD-L1 gene-silencing effect at both mRNA and protein levels in U87 MG cells. Compared with the control cells, the transfected U87 MG cells showed significantly increased vulnerability to the cytotoxicity of human CD8+T cells and an obvious reduction of proliferative activity in the co-culture (P < 0.05).
CONCLUSIONS: Transfection of human glioma U87 MG cells with the specific siRNA targeting PD-L1 obviously enhances the toxicity of human T lymphocytes in the co-culture.

Entities:  

Keywords:  CD8+ T lymphocytes; gliomas; programmed cell death-ligand 1; small interfering RNA

Year:  2018        PMID: 33168513      PMCID: PMC6765535          DOI: 10.3969/j.issn.1673-4254.2018.07.05

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  30 in total

1.  Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference.

Authors:  Kumiko Ui-Tei; Yuki Naito; Fumitaka Takahashi; Takeshi Haraguchi; Hiroko Ohki-Hamazaki; Aya Juni; Ryu Ueda; Kaoru Saigo
Journal:  Nucleic Acids Res       Date:  2004-02-09       Impact factor: 16.971

Review 2.  Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword.

Authors:  Willemijn Hobo; Tim J A Hutten; Nicolaas P M Schaap; Harry Dolstra
Journal:  Br J Haematol       Date:  2018-01-09       Impact factor: 6.998

Review 3.  Coupling of RNA Polymerase II Transcription Elongation with Pre-mRNA Splicing.

Authors:  Tassa Saldi; Michael A Cortazar; Ryan M Sheridan; David L Bentley
Journal:  J Mol Biol       Date:  2016-04-20       Impact factor: 5.469

Review 4.  Overcoming cellular barriers for RNA therapeutics.

Authors:  Steven F Dowdy
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

Review 5.  Silencing human genetic diseases with oligonucleotide-based therapies.

Authors:  Tamara Martínez; Natalia Wright; Marta López-Fraga; Ana Isabel Jiménez; Covadonga Pañeda
Journal:  Hum Genet       Date:  2013-03-14       Impact factor: 4.132

6.  Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy.

Authors:  Dangge Wang; Tingting Wang; Jianping Liu; Haijun Yu; Shi Jiao; Bing Feng; Fangyuan Zhou; Yuanlei Fu; Qi Yin; Pengcheng Zhang; Zhiwen Zhang; Zhaocai Zhou; Yaping Li
Journal:  Nano Lett       Date:  2016-08-17       Impact factor: 11.189

Review 7.  Knocking down disease: a progress report on siRNA therapeutics.

Authors:  Anders Wittrup; Judy Lieberman
Journal:  Nat Rev Genet       Date:  2015-09       Impact factor: 53.242

8.  Avelumab: First Global Approval.

Authors:  Esther S Kim
Journal:  Drugs       Date:  2017-05       Impact factor: 11.431

9.  FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.

Authors:  Yang-Min Ning; Daniel Suzman; V Ellen Maher; Lijun Zhang; Shenghui Tang; Tiffany Ricks; Todd Palmby; Wentao Fu; Qi Liu; Kirsten B Goldberg; Geoffrey Kim; Richard Pazdur
Journal:  Oncologist       Date:  2017-04-19

Review 10.  Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?

Authors:  Matthias Preusser; Anna S Berghoff; Wolfgang Wick; Michael Weller
Journal:  Clin Neuropathol       Date:  2015 Nov-Dec       Impact factor: 1.368

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.